REVB Stock Price, Chart, Stats & News
Revelation Biosciences, Inc. (REVB) does not currently pay a dividend.
REVB chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -0.08% |
ROE | -0.40% |
D/E | 0.08x |
Interest coverage ratio | – |
REVB valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -0.85x |
P/FCF | -0.20x |
P/OCF | -0.85x |
PEG | -0.04x |
EV multiple | 550.50x |
About
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Similar securities
Based on sector and market capitalization
